LLY News and Press, Eli Lilly and Company From 01/15/24

2024-01-15 09:00:00 ET Summary Novo Nordisk stock remains a great buy at every dips, thanks to its expanding 2030 TAM to $150B, highly profitable growth trend, and improving balance sheet. Readers must also note that its growing oral/injectable diabetes/obesity pipelines, with its...

2024-01-15 07:30:03 ET Summary GLP-1 weight-loss drugs have little impact on snack companies like PepsiCo, as consumer habits tend to revert to familiar dietary choices. Monster Energy could see increased demand as weight-loss drugs decrease calorie intake and increase the need fo...

2024-01-15 06:46:00 ET For all of its many successes, the healthcare industry isn't exactly a hotbed of dividend-paying stocks. However, this doesn't mean the sector is entirely without companies that remunerate their shareholders. Some of its larger and more established companies not only ...

2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...

2024-01-14 09:35:00 ET While time in the market is more important than timing the market, sometimes being a little patient is the key to finding a bargain. Right now, you'll pay a pretty penny to invest in high-powered growth stocks, but if you're willing to watch carefully for a few months...

2024-01-14 06:45:00 ET One of the biggest investment themes in 2023 stemmed from the popularity of a new class of obesity and diabetes medications -- a market largely dominated by pharmaceutical juggernauts Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) . Novo Nordis...

2024-01-14 05:40:38 ET Summary Nuveen ESG Large-Cap Growth ETF implements an environmental, social, and corporate governance (“ESG”) approach focused on growth stocks. The strategy starts from a growth index and excludes companies with bad or unknown ESG ratings and ...

2024-01-13 11:42:43 ET Summary CSQ has a solid track record and offers a healthy distribution yield, but it also trades at a tight valuation. The fund's discount has barely budged since our previous update despite the market actually hitting correction territory briefly during thi...

2024-01-13 07:48:00 ET There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY) , Novo Nordisk (NYSE: NVO) , and Vertex Pharmaceuticals...

2024-01-12 13:46:01 ET Summary Pfizer Inc. stock has been on a protracted, yearlong decline due to stronger-than-expected normalization in COVID product uptake rates in 2023. But management's conservative 2024 guidance for COVID product revenues sufficiently de-risks for related h...